Compare Repligen Corporation Common Stock (RGEN) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs T Rowe Price Group Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B), while T Rowe Price Group Inc trades at $100.01 (market cap $21.25B). The key difference: T Rowe Price Group Inc is the larger of the two by market cap, and T Rowe Price Group Inc pays a 5.22% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and T Rowe Price Group Inc for 115 Days on average.
| RGEN | TROW | |
|---|---|---|
Market Cap | $11.31B | $21.25B |
Volume | 1,216,919 | 2,371,937 |
Sector | Health | Financials |
52-Week High | $194.57 | $121.68 |
52-Week Low | $102.87 | $86.19 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $11.20B | $18.45B |
Dividend Yield | — | 5.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
T. Rowe Price (TROW) trades at $101.39, down 2.5% today, showing bearish technical signals with support at $99. Fundamentally, the company maintains strong profitability with 29.3% net margins and ROE of 20.1%, though recent Q4 2025 earnings missed expectations. Revenue growth has been steady, reaching $7.3B in 2025, with positive cash flow trends. Analyst sentiment is mixed with a $110.50 consensus target, representing 9% upside from current levels.
The stock presents a value opportunity with attractive valuation multiples (P/E 10.2x) and dividend yield near 5%, supported by 40 years of dividend growth. Key risks include market-sensitive revenue streams and competitive pressures in asset management. Near-term catalysts include Q3 2026 earnings release and continued ETF expansion through recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
